8-K current report · filed Nov 5, 2026

COLLEGIUM PHARMACEUTICAL, INC (COLL) 8-K Current Report: November 5, 2026

Item 2.02Item 7.01Item EX-99.1Item EX-99.2COLL overview

Short answer

COLLEGIUM PHARMACEUTICAL, INC (COLL) filed an 8-K current report with the SEC on November 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1), Item EX-99.2 (Exhibit EX-99.2). Collegium Pharmaceutical announced financial results for the quarter ended September 30, 2026.

COLLEGIUM PHARMACEUTICAL, INC 8-K event analysis

AI summary of each reported item and its exhibits

Item 2.02 · Results of Operations and Financial Condition

  • Collegium Pharmaceutical announced financial results for the quarter ended September 30, 2026
  • Full quarterly results and management commentary are contained in Exhibit 99.1

Item 7.01 · Regulation FD Disclosure

  • Collegium released an earnings presentation on November 5, 2026
  • Presentation contains the company’s latest earnings-related information and investor messaging
  • Exhibit 99.2 provides the substantive financial and operational details for investor review

Item EX-99.1 · Exhibit EX-99.1

  • Q3 revenue reached a record $216.3M, up 3% year over year, while adjusted EBITDA declined 9% to $121.6M
  • JORNAY PM revenue rose 24% to $51.9M, with prescriptions up 16% and prescribers up 19% to nearly 33,000
  • AZSTARYS generated $26.5M in its first full Collegium-owned quarter, with prescriptions up nearly 2% year over year
  • Pain portfolio revenue fell 18% to $138.0M, driven by Nucynta Franchise revenue declining 44% to $30.8M
  • 2026 guidance reaffirmed: product revenue $825M-$855M and adjusted EBITDA $445M-$470M, alongside a planned $50M share repurchase before year-end

Item EX-99.2 · Exhibit EX-99.2

  • Q3’26 product revenue $216M, up 3% YoY, while adjusted EBITDA fell 9% to $122M on higher adjusted operating expenses
  • 2026 guidance maintained: product revenue $825–855M, adjusted EBITDA $445–470M
  • ADHD expansion gaining traction: JORNAY PM revenue $190–200M guided, AZSTARYS revenue $65–75M after May acquisition
  • AZSTARYS quarterly prescriptions rose 2% to 190K, with patent protection through 2037
  • Capital returns continue: $50M accelerated share repurchase, with $100M remaining under authorization through December 2026

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other COLLEGIUM PHARMACEUTICAL, INC 8-K filings

Get the next COLL 8-K as it lands

Follow COLL for push alerts, or ask the research agent what this filing means.